Creinin M D, Schwartz J L, Pymar H C, Fink W
Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Magee-Womens Hospital, Pennsylvania 15213-3180, USA.
BJOG. 2001 May;108(5):469-73. doi: 10.1111/j.1471-0528.2001.00117.x.
To examine the clinical efficacy of mifepristone 600 mg followed on the same day or two days later by misoprostol 400 microg orally in women undergoing medical termination of pregnancy whose pregnancies have a gestational age up to 49 days.
Prospective, randomised trial.
Clinical research office.
Eighty-six women, requesting elective termination of a pregnancy which has a gestational age of < or = 49 days.
After administration of mifepristone 600 mg, participants were randomised to take misoprostol six to eight hours later (Group 1) or 48 hours later (Group 2). Women returned for a follow up evaluation 24 +/- 1 hours after taking the misoprostol. Participants in Group 1 who had not aborted received a second dose of misoprostol to take 48 hours after the mifepristone. All women returned approximately two weeks after receiving mifepristone. If termination of pregnancy had still not occurred and the pregnancy was non-viable, the woman returned again in three weeks.
Rate of complete abortion 24 hours after administration of misoprostol.
At 24 hours after receiving misoprostol, 21/42 (50%, 95% CI 35%, 65%) women in Group I and 40/44 (91%, 95% CI 82%, 99%) women in Group 2 had complete abortions. By follow up two weeks later after the administration of mifepristone, 40/42 (95%, 95% CI 89%, 100%) women in Group 1 and 43/44 (98%, 95% CI 93%, 99%) women in Group 2 were known to have complete abortions. Nausea, vomiting or diarrhoea in women using the standard regimen (Group 2) occurred in 68%, 36%, and 20%, respectively.
After treatment with mifepristone 600 mg, administration of misoprostol 400 microg orally on the same day is not as effective at causing abortion within the first 24 hours compared with the standard time interval of 48 hours between medications.
探讨米非司酮600毫克,在同一天或两天后口服米索前列醇400微克,用于妊娠49天内接受药物流产的妇女的临床疗效。
前瞻性随机试验。
临床研究办公室。
86名要求选择性终止妊娠且妊娠孕周≤49天的妇女。
服用米非司酮600毫克后,参与者被随机分为在6至8小时后(第1组)或48小时后(第2组)服用米索前列醇。妇女在服用米索前列醇后24±1小时返回进行随访评估。第1组中未流产的参与者在米非司酮服用48小时后接受第二剂米索前列醇。所有妇女在接受米非司酮后约两周返回。如果仍未发生流产且妊娠不可行,该妇女在三周后再次返回。
米索前列醇给药后24小时的完全流产率。
在接受米索前列醇后24小时,第1组中21/42(50%,95%CI 35%,65%)的妇女和第2组中40/44(91%,95%CI 82%,99%)的妇女完全流产。在服用米非司酮两周后的随访中,第1组中40/42(95%,95%CI 89%,100%)的妇女和第2组中43/44(98%,95%CI 93%,99%)的妇女已知完全流产。采用标准方案(第2组)的妇女中恶心、呕吐或腹泻的发生率分别为68%、36%和20%。
与药物之间48小时的标准时间间隔相比,服用600毫克米非司酮后,同一天口服400微克米索前列醇在最初24小时内引起流产的效果不佳。